News

Clinical Trials Arena on MSN11h
First subject dosed in Amylyx’s Phase I trial of ALS therapy
The trial will explore the ALS biomarkers, including the change from baseline in levels of neurofilament light chain.
Amyotrophic Lateral Sclerosis Market To Surge From $0.94 Billion To $1.25 Billion By 2032, MRFR Study Reveals
Amyotrophic_Lateral_Sclerosis_Market_ MRFR reveals steady growth in the ALS market, projecting an increase from $0.94 billion in 2023 to $1 ...
Neurology Advisor2d
Oral Edaravone Safe in Amyotrophic Lateral Sclerosis Through 144 Weeks
The use of oral edaravone for a total of 144 weeks is safe and well-tolerated among patients with amyotrophic lateral ...
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of ...
FreshFruitPortal.com10h
Study shows compound found in certain fruits and vegetables could slow ALS and dementia
A natural compound found in everyday fruits and vegetables may hold the key to protecting nerve cells — and it’s showing ...
Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE 515
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune ...
Science Daily2d
ALS drug effectively treats Alzheimer's disease in new animal study
Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...
YourValley.net9d
Chandler nurse helps make multiple sclerosis manageable
At one point during her health journey, Chandler resident Erin Kienlen thought she had amyotrophic lateral sclerosis, or ALS.